|
1
|
Antoni S, Ferlay J, Soerjomataram I, Znaor
A, Jemal A and Bray F: Bladder cancer incidence and mortality: A
global overview and recent trends. Eur Urol. 71:96–108.
2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Cumberbatch MG, Rota M, Catto JW and La
Vecchia C: The role of tobacco smoke in bladder and kidney
carcinogenesis: A comparison of exposures and meta-analysis of
incidence and mortality risks. Eur Urol. 70:458–466.
2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Humphrey PA, Moch H, Cubilla AL, Ulbright
TM and Reuter VE: The 2016 WHO classification of tumours of the
urinary system and male genital organs-part B: Prostate and bladder
tumours. Eur Urol. 70:106–119. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Flaig TW, Spiess PE, Agarwal N, Bangs R,
Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA,
Friedlander T, et al: Bladder cancer, version 3.2020, NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw.
18:329–354. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Braissant O, Foufelle F, Scotto C, Dauça M
and Wahli W: Differential expression of peroxisome
proliferator-activated receptors (PPARs): tissue distribution of
PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology.
137:354–366. 1996.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sarraf P, Mueller E, Jones D, King FJ,
DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C
and Spiegelman BM: Differentiation and reversal of malignant
changes in colon cancer through PPARgamma. Nat Med. 4:1046–1052.
1998.PubMed/NCBI View
Article : Google Scholar
|
|
7
|
Theocharis S, Giaginis C, Parasi A,
Margeli A, Kakisis J, Agapitos E and Kouraklis G: Expression of
peroxisome proliferator-activated receptor-gamma in colon cancer:
Correlation with histopathological parameters, cell cycle-related
molecules, and patients' survival. Dig Dis Sci. 52:2305–2311.
2007.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Tsukahara T, Haniu H and Matsuda Y:
PTB-associated splicing factor (PSF) is a PPARγ-binding protein and
growth regulator of colon cancer cells. PLoS One.
8(e58749)2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Lv S, Wang W, Wang H, Zhu Y and Lei C:
PPARγ activation serves as therapeutic strategy against bladder
cancer via inhibiting PI3K-Akt signaling pathway. BMC Cancer.
19(204)2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Dong F, Chen L, Wang R, Yang W, Lu T and
Zhang Y: 4-nitrophenol exposure in T24 human bladder cancer cells
promotes proliferation, motilities, and epithelial-to-mesenchymal
transition. Environ Mol Mutagen. 61:316–328. 2020.PubMed/NCBI View
Article : Google Scholar
|
|
11
|
Zhang GY, Ahmed N, Riley C, Oliva K,
Barker G, Quinn MA and Rice GE: Enhanced expression of peroxisome
proliferator-activated receptor gamma in epithelial ovarian
carcinoma. Br J Cancer. 92:113–119. 2005.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Armes JE, Trute L, White D, Southey MC,
Hammet F, Tesoriero A, Hutchins AM, Dite GS, McCredie MR, Giles GG,
et al: Distinct molecular pathogeneses of early-onset breast
cancers in BRCA1 and BRCA2 mutation carriers: A population-based
study. Cancer Res. 59:2011–2017. 1999.PubMed/NCBI
|
|
13
|
Koyama Y, Morikawa T, Miyakawa J, Miyama
Y, Nakagawa T, Homma Y and Fukayama M: Diagnostic utility of Ki-67
immunohistochemistry in small endoscopic biopsies of the ureter and
renal pelvis. Pathol Res Pract. 213:737–741. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Krabbe LM, Bagrodia A, Lotan Y, Gayed BA,
Darwish OM, Youssef RF, John G, Harrow B, Jacobs C, Gaitonde M, et
al: Prospective analysis of Ki-67 as an independent predictor of
oncologic outcomes in patients with high grade upper tract
urothelial carcinoma. J Urol. 191:28–34. 2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Robertson AG, Kim J, Al-Ahmadie H,
Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA,
Akbani R, et al: Comprehensive molecular characterization of
muscle-invasive bladder cancer. Cell. 171:540–556.e25.
2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Cancer Genome Atlas Research Network.
Comprehensive molecular characterization of urothelial bladder
carcinoma. Nature. 507:315–322. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hoadley KA, Yau C, Hinoue T, Wolf DM,
Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, et
al: Cell-of-origin patterns dominate the molecular classification
of 10,000 tumors from 33 types of cancer. Cell. 173:291–304.
2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ellrott K, Bailey MH, Saksena G, Covington
KR, Kandoth C, Stewart C, Hess J, Ma S, Chiotti KE, McLellan M, et
al: Scalable open science approach for mutation calling of tumor
exomes using multiple genomic pipelines. Cell Syst. 6:271–281.e7.
2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Taylor AM, Shih J, Ha G, Gao GF, Zhang X,
Berger AC, Schumacher SE, Wang C, Hu H, Liu J, et al: Genomic and
functional approaches to understanding cancer aneuploidy. Cancer
Cell. 33:676–689.e3. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Liu J, Lichtenberg T, Hoadley KA, Poisson
LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee
AV, et al: An integrated TCGA Pan-cancer clinical data resource to
drive high-quality survival outcome analytics. Cell.
173:400–416.e11. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Sanchez-Vega F, Mina M, Armenia J, Chatila
WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia
S, et al: Oncogenic signaling pathways in the cancer genome atlas.
Cell. 173:321–337.e10. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Gao Q, Liang WW, Foltz SM, Mutharasu G,
Jayasinghe RG, Cao S, Liao WW, Reynolds SM, Wyczalkowski MA, Yao L,
et al: Driver fusions and their implications in the development and
treatment of human cancers. Cell Rep. 23:227–238.e3.
2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Poore GD, Kopylova E, Zhu Q, Carpenter C,
Fraraccio S, Wandro S, Kosciolek T, Janssen S, Metcalf J, Song SJ,
et al: Microbiome analyses of blood and tissues suggest cancer
diagnostic approach. Nature. 579:567–574. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ding L, Bailey MH, Porta-Pardo E, Thorsson
V, Colaprico A, Bertrand D, Gibbs DL, Weerasinghe A, Huang KL,
Tokheim C, et al: Perspective on oncogenic processes at the end of
the beginning of cancer genomics. Cell. 173:305–320.e10.
2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Bonneville R, Krook MA, Kautto EA, Miya J,
Wing MR, Chen HZ, Reeser JW, Yu L and Roychowdhury S: Landscape of
microsatellite instability across 39 cancer types. JCO Precis
Oncol: Oct 3, 2017 (Epub ahead of print). doi:
10.1200/PO.17.00073.
|
|
27
|
Yun SH, Roh MS, Jeong JS and Park JI:
Peroxisome proliferator-activated receptor γ coactivator-1α is a
predictor of lymph node metastasis and poor prognosis in human
colorectal cancer. Ann Diagn Pathol. 33:11–16. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Michael MS, Badr MZ and Badawi AF:
Inhibition of cyclooxygenase-2 and activation of peroxisome
proliferator-activated receptor-gamma synergistically induces
apoptosis and inhibits growth of human breast cancer cells. Int J
Mol Med. 11:733–736. 2003.PubMed/NCBI
|
|
29
|
Tsubouchi Y, Sano H, Kawahito Y, Mukai S,
Yamada R, Kohno M, Inoue K, Hla T and Kondo M: Inhibition of human
lung cancer cell growth by the peroxisome proliferator-activated
receptor-gamma agonists through induction of apoptosis. Biochem
Biophys Res Commun. 270:400–405. 2000.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Grimm S, Bauer MK, Baeuerle PA and
Schulze-Osthoff K: Bcl-2 down-regulates the activity of
transcription factor NF-kappaB induced upon apoptosis. J Cell Biol.
134:13–23. 1996.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Chen GG, Lee JF, Wang SH, Chan UP, Ip PC
and Lau WY: Apoptosis induced by activation of
peroxisome-proliferator activated receptor-gamma is associated with
Bcl-2 and NF-kappaB in human colon cancer. Life Sci. 70:2631–2646.
2002.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Catz SD and Johnson JL: Transcriptional
regulation of bcl-2 by nuclear factor kappa B and its significance
in prostate cancer. Oncogene. 20:7342–7351. 2001.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Nakashiro KI, Hayashi Y, Kita A, Tamatani
T, Chlenski A, Usuda N, Hattori K, Reddy JK and Oyasu R: Role of
peroxisome proliferator-activated receptor gamma and its ligands in
non-neoplastic and neoplastic human urothelial cells. Am J Pathol.
159:591–597. 2001.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Wang G, Cao R, Wang Y, Qian G, Dan HC,
Jiang W, Ju L, Wu M, Xiao Y and Wang X: Simvastatin induces cell
cycle arrest and inhibits proliferation of bladder cancer cells via
PPARγ signalling pathway. Sci Rep. 6(35783)2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Castillo-Martin M, Domingo-Domenech J,
Karni-Schmidt O, Matos T and Cordon-Cardo C: Molecular pathways of
urothelial development and bladder tumorigenesis. Urol Oncol.
28:401–408. 2010.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Spruck CH III, Ohneseit PF,
Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmütte
C, Yang AS, Cote R, et al: Two molecular pathways to transitional
cell carcinoma of the bladder. Cancer Res. 54:784–788.
1994.PubMed/NCBI
|
|
37
|
Mylona E, Giannopoulou I, Diamantopoulou
K, Bakarakos P, Nomikos A, Zervas A and Nakopoulou L: Peroxisome
proliferator-activated receptor gamma expression in urothelial
carcinomas of the bladder: Association with differentiation,
proliferation and clinical outcome. Eur J Surg Oncol. 35:197–201.
2009.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Kim M, Ro JY, Amin MB, de
Peralta-Venturina M, Kwon GY, Park YW and Cho YM: Urothelial eddies
in papillary urothelial neoplasms: A distinct morphologic pattern
with low risk for progression. Int J Clin Exp Pathol. 6:1458–1466.
2013.PubMed/NCBI
|
|
39
|
Shim JW, Cho KS, Choi YD, Park YW, Lee DW,
Han WS, Shim SI, Kim HJ and Cho NH: Diagnostic algorithm for
papillary urothelial tumors in the urinary bladder. Virchows Arch.
452:353–362. 2008.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Goussia AC, Papoudou-Bai A, Charchanti A,
Kitsoulis P, Kanavaros P, Kalef-Ezra J, Stefanou D and Agnantis NJ:
Alterations of p53 and Rb pathways are associated with high
proliferation in bladder urothelial carcinomas. Anticancer Res.
38:3985–3988. 2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Quintero A, Alvarez-Kindelan J, Luque RJ,
Gonzalez-Campora R, Requena MJ, Montironi R and Lopez-Beltran A:
Ki-67 MIB1 labelling index and the prognosis of primary TaT1
urothelial cell carcinoma of the bladder. J Clin Pathol. 59:83–88.
2006.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Ogata DC, Marcondes CA, Tuon FF, Busato WF
Jr, Cavalli G and Czeczko LE: Superficial papillary urothelial
neoplasms of the bladder (PTA E PT1): Correlation of expression of
P53, KI-67 and CK20 with histologic grade, recurrence and tumor
progression. Rev Col Bras Cir. 39:394–400. 2012.PubMed/NCBI View Article : Google Scholar : (In English,
Portuguese).
|
|
43
|
Sato M, Yanai H, Morito T, Oda W, Shin-no
Y, Yamadori I, Tshushima T and Yoshino T: Association between the
expression pattern of p16, pRb and p53 and the response to
intravesical bacillus Calmette-Guerin therapy in patients with
urothelial carcinoma in situ of the urinary bladder. Pathol Int.
61:456–460. 2011.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Meuleman EJ and Delaere KP: Diagnostic
efficacy of the combination of urine cytology, urine analysis and
history in the follow-up of bladder carcinoma. Br J Urol.
62:150–153. 1988.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Wiener HG, Mian C, Haitel A, Pycha A,
Schatzl G and Marberger M: Can urine bound diagnostic tests replace
cystoscopy in the management of bladder cancer? J Urol.
159:1876–1880. 1998.PubMed/NCBI
|
|
46
|
Yamashiro K, Taira K, Nakajima M, Azuma M,
Koseki M, Abe T, Suzuki H, Minami K, Harabayashi T and Nagamori S:
Voided urine cytology and low-grade urothelial neoplasia of the
bladder: Factors that influence the sensitivity. J Am Soc
Cytopathol. 5:227–234. 2016.PubMed/NCBI View Article : Google Scholar
|
